pharma · Recurrent Pericarditis · Sjögren’s Disease · KNSA
Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International patent portfolio — 9 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 100 Hayden Ave, Lexington, Massachusetts 02421, US
- Founded
- 2015
- Employees
- 381
- Programs
- 14
- Drugs
- 7
- Patents
- 9
Kiniksa Pharmaceuticals International patents
9 pharmaceutical patents indexed for Kiniksa Pharmaceuticals International. 0 expire within 24 months.
Kiniksa Pharmaceuticals International has 9 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12234294
Pharmaceutical composition of a humanized anti-CD40 antibody
granted -
US 12122837
Oncostatin M receptor antigen binding proteins
granted -
US 11141479
Stable anti-OSMR antibody formulation
granted -
US 10493149
Stable anti-OSMR antibody formulation
granted -
US 10421813
Oncostatin M receptor antigen binding proteins
granted -
US 10391170
Stable anti-OSMR antibody formulation
granted -
US 9738721
Oncostatin M receptor antigen binding proteins
granted -
US 9663571
Oncostatin M receptor antigen binding proteins
granted -
US 9593163
Oncostatin M receptor antigen binding proteins
granted
Frequently asked questions
How many patents does Kiniksa Pharmaceuticals International have?
9 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Kiniksa Pharmaceuticals International patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.